Jubilant Pharmova Limited Approves ₹800 Crore NCD Issuance
1 report, 1 independent
Updated Oct 12
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The board of directors of Jubilant Pharmova Limited approved the issuance of Non-Convertible Debentures (NCDs) on a private placement basis. The proposed issuance includes up to 80,000 rupee-denominated debentures, aggregating up to ₹800 crore, which are planned for listing on BSE Limited. The board also authorized seeking member approval for a larger issuance of up to ₹2,500 crore over a one-year period.
From equitybulls.com
Why it matters
The approval allows Jubilant Pharmova Limited to raise significant capital through debt financing. The NCDs have a tenure of up to five years, and the coupon rate will be set during the bidding process.
From equitybulls.com
Who's involved
- board of directorsThe board of directors approved the debt issuance and sought member authorization for the company.
- companyThe company is the issuer of the Non-Convertible Debentures.
Keep exploring
The entities involved
-
board of directors
group of people who jointly supervise the activities of an organization